| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1110565547 |
| P356 | DOI | 10.1186/S13024-018-0299-8 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s13024-018-0299-8 |
| P932 | PMC publication ID | 6291983 |
| P698 | PubMed publication ID | 30541602 |
| P50 | author | Dongming Cai | Q59696230 |
| P2093 | author name string | Jianwei Hou | |
| Jing Ping | |||
| Jiqing Cao | |||
| P2860 | cites work | Recent developments of protein kinase inhibitors as potential AD therapeutics | Q21129481 |
| A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease | Q21146622 | ||
| Noninvasive 40-Hz light flicker to recruit microglia and reduce amyloid beta load | Q90724248 | ||
| Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease | Q22242287 | ||
| Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state | Q22254058 | ||
| Statins for the prevention of dementia | Q24241335 | ||
| Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau | Q24294296 | ||
| Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain | Q24308258 | ||
| Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice | Q24338349 | ||
| Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence | Q24601034 | ||
| ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models | Q24628845 | ||
| ApoE promotes the proteolytic degradation of Abeta | Q24651102 | ||
| Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease | Q24656640 | ||
| Gleevec inhibits β-amyloid production but not Notch cleavage | Q24683037 | ||
| Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease | Q26739412 | ||
| Current Research Therapeutic Strategies for Alzheimer's Disease Treatment | Q26765530 | ||
| The genetic landscape of Alzheimer disease: clinical implications and perspectives | Q26796582 | ||
| N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease | Q26825619 | ||
| Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease | Q26858870 | ||
| Testing the right target and right drug at the right stage | Q26864854 | ||
| Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease | Q26866265 | ||
| Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment | Q27301070 | ||
| Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits | Q27314989 | ||
| Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy | Q27316185 | ||
| Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor | Q27675616 | ||
| The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans | Q27697610 | ||
| Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8 | Q27703671 | ||
| The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease | Q28005463 | ||
| Tau Biology and Tau-Directed Therapies for Alzheimer's Disease | Q28071398 | ||
| Neuroprotective Mechanisms Mediated by CDK5 Inhibition | Q28082792 | ||
| Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models | Q28119018 | ||
| Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1 | Q28139001 | ||
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium | Q28252389 | ||
| Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein | Q28260479 | ||
| Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial | Q34442517 | ||
| Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease | Q34456081 | ||
| MIND diet associated with reduced incidence of Alzheimer's disease | Q34462761 | ||
| Fyn inhibition rescues established memory and synapse loss in Alzheimer mice | Q34464152 | ||
| The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease | Q34469528 | ||
| MIND diet slows cognitive decline with aging | Q34481228 | ||
| Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease | Q34490776 | ||
| Vitamin E for Alzheimer's dementia and mild cognitive impairment. | Q34550138 | ||
| Nitric oxide and nitroxidative stress in Alzheimer's disease. | Q34579767 | ||
| Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. | Q34605131 | ||
| Insulin resistance in Alzheimer's disease | Q34622157 | ||
| The γ-secretase complex: from structure to function | Q34677532 | ||
| CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis | Q34796584 | ||
| Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. | Q35029780 | ||
| Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques | Q35030015 | ||
| Higher seizure susceptibility and enhanced tyrosine phosphorylation of N-methyl-D-aspartate receptor subunit 2B in fyn transgenic mice | Q35038945 | ||
| Neurotrophins, neuroprotection and the blood-brain barrier | Q35045242 | ||
| Epidemiology of neurodegeneration | Q35062651 | ||
| A common thread for pain and memory synapses? Brain-derived neurotrophic factor and trkB receptors. | Q35082160 | ||
| Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice | Q35095392 | ||
| Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study | Q35107521 | ||
| A reduced astrocyte response to β-amyloid plaques in the ageing brain associates with cognitive impairment | Q35112550 | ||
| Neurotrophic factors as novel therapeutics for neuropathic pain | Q35140851 | ||
| Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease | Q35157420 | ||
| Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice | Q35166985 | ||
| Human apoE isoforms differentially regulate brain amyloid-β peptide clearance | Q35334161 | ||
| 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease | Q35622640 | ||
| Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease | Q35658184 | ||
| Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial | Q35679839 | ||
| Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations | Q35745983 | ||
| Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease | Q35749213 | ||
| Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease | Q35804446 | ||
| Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay | Q35857978 | ||
| Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy | Q35905639 | ||
| The role of inflammation in Alzheimer's disease | Q35913633 | ||
| APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics | Q35997607 | ||
| Trans-cellular propagation of Tau aggregation by fibrillar species | Q36003836 | ||
| E-pharmacophore-based virtual screening to identify GSK-3β inhibitors | Q36053324 | ||
| Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice | Q36065117 | ||
| Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01 | Q36068420 | ||
| Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis | Q36102989 | ||
| Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans | Q36152393 | ||
| Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials | Q36334769 | ||
| Mechanism of action of memantine | Q36348056 | ||
| Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides | Q36386913 | ||
| Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis | Q36409002 | ||
| APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. | Q36451896 | ||
| Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. | Q36492888 | ||
| Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease | Q36517542 | ||
| Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature | Q36575903 | ||
| Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing | Q36579740 | ||
| Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1 | Q36600444 | ||
| Neuroinflammatory phenotype in early Alzheimer's disease | Q36629135 | ||
| Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples | Q36635968 | ||
| The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. | Q36683246 | ||
| Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration | Q36817618 | ||
| Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss | Q36877497 | ||
| Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease | Q36914722 | ||
| Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice | Q36958249 | ||
| A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome | Q37008339 | ||
| Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury | Q37008474 | ||
| Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs | Q37083428 | ||
| The neuroprotective mechanism of action of the multimodal drug ladostigil | Q37175479 | ||
| p70 S6 kinase and tau in Alzheimer's disease. | Q37238266 | ||
| Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure | Q37307244 | ||
| A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease | Q37345118 | ||
| Physical activity, diet, and risk of Alzheimer disease | Q37394712 | ||
| Developing novel immunogens for a safe and effective Alzheimer's disease vaccine | Q37574391 | ||
| Phosphodiesterases as therapeutic targets for Alzheimer's disease | Q28279704 | ||
| Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy | Q28282855 | ||
| The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease | Q28294536 | ||
| Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor | Q28573596 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease | Q29614374 | ||
| The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
| Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial | Q29617817 | ||
| Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 | ||
| CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance | Q29620412 | ||
| Alzheimer's disease | Q30251865 | ||
| Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance | Q30274556 | ||
| Ginkgo biloba for prevention of dementia: a randomized controlled trial | Q30437036 | ||
| Apolipoprotein E4 domain interaction: synaptic and cognitive deficits in mice | Q30486146 | ||
| ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice | Q30497102 | ||
| Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy | Q30499456 | ||
| Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors | Q30500121 | ||
| Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial | Q30559265 | ||
| Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial | Q30584897 | ||
| Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice | Q30611779 | ||
| Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data | Q30616078 | ||
| Potential for primary prevention of Alzheimer's disease: an analysis of population-based data | Q30836810 | ||
| Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor | Q31451987 | ||
| A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence | Q33165693 | ||
| Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. | Q33243843 | ||
| Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. | Q33549121 | ||
| Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment | Q33556068 | ||
| Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor | Q33558208 | ||
| Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis | Q33639513 | ||
| A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. | Q33664194 | ||
| Neurotrophins and hyperalgesia. | Q33679514 | ||
| Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease | Q33732191 | ||
| Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults | Q33747998 | ||
| Systemic inflammation and disease progression in Alzheimer disease | Q33765718 | ||
| Adherence to a Mediterranean diet, cognitive decline, and risk of dementia | Q33772800 | ||
| Meta-analysis of apolipoprotein E levels in the cerebrospinal fluid of patients with Alzheimer's disease. | Q38685022 | ||
| Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. | Q38960994 | ||
| Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends | Q39022532 | ||
| Physical Activity and Alzheimer's Disease: A Systematic Review | Q39066255 | ||
| The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients | Q39222469 | ||
| Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls | Q39230272 | ||
| Propagation of Tau aggregates | Q39338832 | ||
| Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline | Q39694072 | ||
| COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury | Q40111724 | ||
| Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. | Q40273314 | ||
| Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation | Q40601680 | ||
| Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. | Q40690737 | ||
| Anti-tau antibody reduces insoluble tau and decreases brain atrophy | Q41150186 | ||
| Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis | Q41365399 | ||
| Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology | Q41762801 | ||
| Anti-inflammatory impact of minocycline in a mouse model of tauopathy. | Q41854166 | ||
| Cellular assays for high-throughput screening for modulators of Trk receptor tyrosine kinases | Q41863058 | ||
| Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. | Q41955482 | ||
| Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology | Q42008541 | ||
| A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease | Q42244023 | ||
| Paradoxical effect of TrkA inhibition in Alzheimer's disease models | Q42278279 | ||
| Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae | Q42379648 | ||
| Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. | Q42436485 | ||
| Role of TGFβ signaling in the pathogenesis of Alzheimer's disease. | Q42586333 | ||
| Gamma frequency entrainment attenuates amyloid load and modifies microglia | Q42631490 | ||
| A phase 3 trial of semagacestat for treatment of Alzheimer's disease | Q42710153 | ||
| Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. | Q42939448 | ||
| Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function | Q43085965 | ||
| Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. | Q43239295 | ||
| Regulatory innovation and drug development for early-stage Alzheimer's disease | Q43438827 | ||
| Mapping ApoE/Aβ binding regions to guide inhibitor discovery. | Q43508053 | ||
| Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain | Q43516537 | ||
| A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity | Q43793656 | ||
| The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice | Q44557277 | ||
| PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer's disease transgenic mice | Q44962410 | ||
| A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease | Q45883058 | ||
| Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. | Q45908140 | ||
| Can lithium or valproate untie tangles in Alzheimer's disease? | Q45941985 | ||
| A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. | Q45970893 | ||
| A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study | Q46077947 | ||
| Propagation of Tau Aggregates and Neurodegeneration | Q46095913 | ||
| Dimebon attenuates the Aβ-induced mitochondrial permeabilization | Q46176288 | ||
| Activation of Fyn tyrosine kinase in the mouse dorsal hippocampus is essential for contextual fear conditioning. | Q46437578 | ||
| Microglia-Mediated Neuroprotection, TREM2, and Alzheimer's Disease: Evidence From Optical Imaging | Q46598391 | ||
| A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia | Q46924783 | ||
| Intranasal insulin improves cognition and modulates beta-amyloid in early AD. | Q46945303 | ||
| Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice | Q47547728 | ||
| Profiles of β-Amyloid Peptides and Key Secretases in Brain Autopsy Samples Differ with Sex and APOE ε4 Status: Impact for Risk and Progression of Alzheimer Disease | Q47553867 | ||
| Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials | Q47557467 | ||
| Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. | Q47767946 | ||
| Astrocyte modulation of in vitro beta-amyloid neurotoxicity | Q47866925 | ||
| Tau passive immunization inhibits not only tau but also Aβ pathology | Q37579019 | ||
| The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives | Q37656554 | ||
| Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward | Q37670673 | ||
| Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology | Q37682942 | ||
| Fyn kinase inhibition as a novel therapy for Alzheimer's disease | Q37689640 | ||
| A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy | Q37695237 | ||
| Formation and function of apolipoprotein E-containing lipoproteins in the nervous system | Q37695376 | ||
| Alzheimer's disease: theories of causation | Q37794506 | ||
| The many substrates of presenilin/γ-secretase | Q37845036 | ||
| Combination therapy for Alzheimer's disease | Q37896602 | ||
| Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment | Q37978935 | ||
| Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial | Q38041758 | ||
| What causes alzheimer's disease? | Q38151565 | ||
| Microglia actions in Alzheimer’s disease. | Q38162232 | ||
| Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases | Q38168475 | ||
| Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk | Q38175420 | ||
| Active immunotherapy options for Alzheimer's disease | Q38183140 | ||
| Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines | Q38187861 | ||
| ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? | Q38190156 | ||
| Multifunctional compounds: smart molecules for multifactorial diseases | Q38190722 | ||
| Microglial priming in neurodegenerative disease | Q38196699 | ||
| Innate immune activation in neurodegenerative disease | Q38223011 | ||
| Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? | Q38224958 | ||
| The APOE genotype: modification of therapeutic responses in Alzheimer's disease | Q38261442 | ||
| Invited review: Drug development for tauopathies | Q38263698 | ||
| Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication | Q38286246 | ||
| Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. | Q38380454 | ||
| Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence | Q38407177 | ||
| Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease | Q38465993 | ||
| AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor. | Q38608720 | ||
| Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease. | Q38639674 | ||
| Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease | Q38643963 | ||
| Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease | Q33789329 | ||
| Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation | Q33856674 | ||
| NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type | Q33881607 | ||
| Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease | Q33894236 | ||
| Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice | Q33906674 | ||
| Drug candidates in clinical trials for Alzheimer's disease | Q33916749 | ||
| Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup | Q33969633 | ||
| Sex modifies the APOE-related risk of developing Alzheimer disease | Q33984761 | ||
| Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial | Q33988701 | ||
| Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial | Q34013637 | ||
| Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials | Q34014237 | ||
| The apoE-mimetic peptide, COG1410, improves functional recovery in a murine model of intracerebral hemorrhage | Q34046878 | ||
| Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo | Q34063772 | ||
| A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression | Q34083364 | ||
| Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. | Q34096644 | ||
| Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline | Q34113201 | ||
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
| Regulation of tau pathology by the microglial fractalkine receptor | Q34179654 | ||
| CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. | Q34254575 | ||
| 2012 Alzheimer's disease facts and figures | Q34260109 | ||
| Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. | Q34296827 | ||
| The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. | Q34312604 | ||
| Deaths: final data for 2008. | Q34342648 | ||
| Complexity of receptor tyrosine kinase signal processing | Q34361161 | ||
| Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease | Q34366768 | ||
| 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease | Q34370099 | ||
| Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. | Q34431008 | ||
| Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease | Q47940819 | ||
| A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease | Q48136103 | ||
| Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems | Q48250150 | ||
| The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease | Q48254282 | ||
| Inverse and distinct modulation of tau-dependent neurodegeneration by presenilin 1 and amyloid-beta in cultured cortical neurons: evidence that tau phosphorylation is the limiting factor in amyloid-beta-induced cell death | Q48273890 | ||
| Effects of PS1 deficiency on membrane protein trafficking in neurons | Q48327056 | ||
| An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction | Q48328723 | ||
| Early-stage and preclinical Alzheimer disease | Q48342215 | ||
| Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial | Q48359732 | ||
| Association of the CX3CR1-V249I Variant with Neurofibrillary Pathology Progression in Late-Onset Alzheimer's Disease | Q48361868 | ||
| No significant effect of 7,8-dihydroxyflavone on APP processing and Alzheimer-associated phenotypes. | Q48406899 | ||
| GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia. | Q48440377 | ||
| Liver X receptor activation restores memory in aged AD mice without reducing amyloid. | Q48487098 | ||
| The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. | Q48498115 | ||
| The role of astrocytes in amyloid β-protein toxicity and clearance. | Q48520121 | ||
| Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. | Q48532697 | ||
| Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. | Q48842824 | ||
| Ligand-dependent TrkA activity in brain differentially affects spatial learning and long-term memory. | Q48863337 | ||
| Neurodegenerative disease: Tau immunotherapy targets transcellular propagation. | Q48872610 | ||
| Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer's disease. | Q48924410 | ||
| Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. | Q49067543 | ||
| Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice. | Q50045202 | ||
| BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. | Q50422623 | ||
| A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. | Q50578805 | ||
| Nerve growth factor and neurotrophin-3 mediate survival of pulmonary plasma cells during the allergic airway inflammation. | Q51738248 | ||
| Comparison of the design differences between the Ginkgo Evaluation of Memory study and the GuidAge study. | Q51968280 | ||
| Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. | Q52629028 | ||
| Low molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activity. | Q53332566 | ||
| Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. | Q53341825 | ||
| Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics. | Q53396708 | ||
| Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. | Q53414759 | ||
| SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy. | Q54255866 | ||
| Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein. | Q55118610 | ||
| The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review. | Q55381143 | ||
| Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus | Q56004691 | ||
| Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work | Q57897029 | ||
| BDNF: a neuromodulator in nociceptive pathways? | Q57898658 | ||
| Author Correction: Gamma frequency entrainment attenuates amyloid load and modifies microglia | Q59055882 | ||
| Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection | Q59357082 | ||
| Molecular genetics of Alzheimer's disease | Q72371630 | ||
| Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans | Q73089963 | ||
| S100beta induces neuronal cell death through nitric oxide release from astrocytes | Q73892793 | ||
| Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1 | Q73949956 | ||
| Nerve growth factor evokes hyperalgesia in mice lacking the low-affinity neurotrophin receptor p75 | Q77623877 | ||
| Semagacestat for treatment of Alzheimer's disease | Q86576192 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| molecular biology | Q7202 | ||
| biomedical investigative technique | Q66648976 | ||
| disease progression | Q86758334 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 64 | |
| P577 | publication date | 2018-12-12 | |
| P1433 | published in | Molecular Neurodegeneration | Q15817329 |
| P1476 | title | Advances in developing novel therapeutic strategies for Alzheimer's disease | |
| P478 | volume | 13 |
| Q90114556 | A Network-Based Approach to Explore the Mechanisms of Uncaria Alkaloids in Treating Hypertension and Alleviating Alzheimer's Disease |
| Q92327129 | Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement |
| Q90263995 | Appoptosin Mediates Lesions Induced by Oxidative Stress Through the JNK-FoxO1 Pathway |
| Q91893833 | Bazhu Decoction, a Traditional Chinese Medical Formula, Ameliorates Cognitive Deficits in the 5xFAD Mouse Model of Alzheimer's Disease |
| Q98178405 | Brain-Derived Neurotrophic Factor (BDNF) Preserves the Functional Integrity of Neural Networks in the β-Amyloidopathy Model in vitro |
| Q91707000 | Dreaming of a New World Where Alzheimer's Is a Treatable Disorder |
| Q89944288 | Endogenous 3-Iodothyronamine (T1AM) and Synthetic Thyronamine-like Analog SG-2 Act as Novel Pleiotropic Neuroprotective Agents Through the Modulation of SIRT6 |
| Q92535560 | Friend, Foe or Both? Immune Activity in Alzheimer's Disease |
| Q97423813 | MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer's disease pathogenesis |
| Q97419721 | Periodontal Disease and Periodontal Disease-Related Bacteria Involved in the Pathogenesis of Alzheimer's Disease |
| Q92556485 | Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease |
| Q91962329 | Rapid Identification of Tanshinone IIA Metabolites in an Amyloid-β1-42 Induced Alzherimer's Disease Rat Model using UHPLC-Q-Exactive Qrbitrap Mass Spectrometry |
| Q90252848 | Research Progress on Alzheimer's Disease and Resveratrol |
| Q91695227 | Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer's disease |
| Q90263746 | SNX8 Enhances Non-amyloidogenic APP Trafficking and Attenuates Aβ Accumulation and Memory Deficits in an AD Mouse |
| Q99579313 | Stem cell therapy for Alzheimer's disease |
| Q92898785 | Study on the Multitarget Synergistic Effects of Kai-Xin-San against Alzheimer's Disease Based on Systems Biology |
| Q92132051 | Systems Pharmacology Approach to Investigate the Mechanism of Kai-Xin-San in Alzheimer's Disease |
| Q89619844 | The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer's Disease |
| Q90671783 | Therapeutic Potential of Diosgenin and Its Major Derivatives against Neurological Diseases: Recent Advances |
Search more.